These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Not reported 2006-005991-41 A multicentre, double-blind, placebo-controlled evaluation of intranasal sumatriptan delivered with the OptiNose powder device in the treatment of acute migraine. 2007-09-13 due-trials
Not reported Terminated 2006-006340-60 A Double Blind, Randomised, Parallel Group, Placebo-Controlled Study to Investigate the Efficacy and Tolerability of Intranasal Fluticasone Propionate Delivered by the Optinose Device in Adult Patient... 2009-09-09 due-trials
Reported results 2011-004886-34 A 16-Week RaNdomized, Double-Blind, Placebo-Controlled, PArallel-Group, Multicenter Study EValuatInG the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of FluticAsone Propion... 2015-10-01 due-trials
Reported results 2011-004887-31 A 16-Week RaNdomized, Double-Blind, Placebo-Controlled, PArallel-Group, Multicenter Study EValuatInG the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of FluticAsone Propion... 2015-07-03 due-trials
Not reported 2014-005452-26 A randomized, placebo controlled, double-blind, double-dummy, 3-period cross-over study in adult patients with autism spectrum disorders evaluating cognitive response, eye-gaze, and heart rate variabi... 2016-02-17 due-trials
Ongoing, reported early 2019-000368-12 A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 μg of OPN-375 Twice a Day (BID)... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2019-000648-86 A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 μg of OPN-375 Twice a Day (BID)... 2022-05-04 bad-data